From the Department of Pediatric, Pediatric Critical Care Unit, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Saudi Med J. 2023 May;44(5):440-449. doi: 10.15537/smj.2023.44.5.20220672.
Approximately 25% of all pediatric consultations are due to respiratory conditions, 10% of which are for asthma. Regarding prevalence, bronchiolitis, acute bronchitis, and respiratory infections are other leading pediatric respiratory illnesses. Compared to the aforementioned diseases, pediatric acute respiratory distress syndrome (PARDS) is rare but lethal in the Intensive Care Unit patients. According to global studies, the mortality in PARDS ranges from 13.3% to 60.7%. Before the Pediatric Acute Lung Injury Consensus Conference (PALICC), adult acute respiratory distress syndrome (ARDS) management guidelines were used for PARDS. The PALICC set new criteria to identify PARDS with a different treatment and management approach. Steroids have been used to treat ARDS in some cases, although their effectiveness in treating pediatric patients is highly debated in the scientific community. This review examines steroid use in treating PARDS, emphasizes current developments in the field, and gives a broad overview of PARDS management.
约 25%的儿科就诊是由于呼吸系统疾病引起的，其中 10%是哮喘。关于患病率，细支气管炎、急性支气管炎和呼吸道感染是其他主要的儿科呼吸系统疾病。与上述疾病相比，儿科急性呼吸窘迫综合征（PARDS）在重症监护病房患者中虽然罕见但致命。根据全球研究，PARDS 的死亡率范围在 13.3%至 60.7%之间。在儿科急性肺损伤共识会议（PALICC）之前，成人急性呼吸窘迫综合征（ARDS）管理指南曾用于 PARDS。PALICC 制定了新的标准来识别 PARDS，并采用不同的治疗和管理方法。在某些情况下，类固醇已被用于治疗 ARDS，但在科学界，它们在治疗儿科患者方面的有效性存在很大争议。这篇综述探讨了类固醇在治疗 PARDS 中的应用，强调了该领域的最新发展，并对 PARDS 的管理进行了全面概述。
